MaxCyte, Inc. (MXCT)

MaxCyte Statistics

Total Valuation

MaxCyte has a market cap or net worth of $438.50 million. The enterprise value is $311.39 million.

Market Cap	438.50M
Enterprise Value	311.39M

Important Dates

The last earnings date was Wednesday, November 6, 2024, after market close.

Earnings Date	Nov 6, 2024
Ex-Dividend Date	n/a

Share Statistics

MaxCyte has 105.69 million shares outstanding. The number of shares has increased by 1.47% in one year.

Current Share Class	105.69M
Shares Outstanding	105.69M
Shares Change (YoY)	+1.47%
Shares Change (QoQ)	+0.45%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	96.15M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	10.78
PB Ratio	n/a
P/TBV Ratio	2.06
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	6.83
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 9.81, with a Debt / Equity ratio of 0.09.

Current Ratio	9.81
Quick Ratio	8.99
Debt / Equity	0.09
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -16.00% and return on invested capital (ROIC) is -12.05%.

Return on Equity (ROE)	-16.00%
Return on Assets (ROA)	-11.25%
Return on Capital (ROIC)	-12.05%
Revenue Per Employee	$318,874
Profits Per Employee	-$249,902
Employee Count	143
Asset Turnover	0.18
Inventory Turnover	0.56

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -14.52% in the last 52 weeks. The beta is 1.16, so MaxCyte's price volatility has been higher than the market average.

Beta (5Y)	1.16
52-Week Price Change	-14.52%
50-Day Moving Average	3.75
200-Day Moving Average	4.11
Relative Strength Index (RSI)	60.64
Average Volume (20 Days)	704,746

Short Selling Information

The latest short interest is 3.06 million, so 2.90% of the outstanding shares have been sold short.

Short Interest	3.06M
Short Previous Month	3.32M
Short % of Shares Out	2.90%
Short % of Float	3.18%
Short Ratio (days to cover)	4.08

Income Statement

In the last 12 months, MaxCyte had revenue of $45.60 million and -$35.74 million in losses. Loss per share was -$0.34.

Revenue	45.60M
Gross Profit	39.21M
Operating Income	-46.39M
Pretax Income	-35.43M
Net Income	-35.74M
EBITDA	-42.03M
EBIT	-46.39M
Loss Per Share	-$0.34

Balance Sheet

The company has $153.83 million in cash and $18.32 million in debt, giving a net cash position of $135.51 million or $1.28 per share.

Cash & Cash Equivalents	153.83M
Total Debt	18.32M
Net Cash	135.51M
Net Cash Per Share	$1.28
Equity (Book Value)	213.30M
Book Value Per Share	2.03
Working Capital	155.29M

Cash Flow

In the last 12 months, operating cash flow was -$18.81 million and capital expenditures -$2.42 million, giving a free cash flow of -$21.23 million.

Operating Cash Flow	-18.81M
Capital Expenditures	-2.42M
Free Cash Flow	-21.23M
FCF Per Share	-$0.20

Margins

Gross margin is 85.98%, with operating and profit margins of -101.74% and -78.37%.

Gross Margin	85.98%
Operating Margin	-101.74%
Pretax Margin	-78.37%
Profit Margin	-78.37%
EBITDA Margin	-92.18%
EBIT Margin	-101.74%
FCF Margin	n/a

Dividends & Yields

MaxCyte does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.47%
Shareholder Yield	-1.47%
Earnings Yield	-8.15%
FCF Yield	-4.84%

Analyst Forecast

The average price target for MaxCyte is $9.50, which is 124.06% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$9.50
Price Target Difference	124.06%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	29.33%
EPS Growth Forecast (5Y)	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

MaxCyte has an Altman Z-Score of 6.72 and a Piotroski F-Score of 2.

Altman Z-Score	6.72
Piotroski F-Score	2